Search Results

• • 74 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Clinical Characteristics in Patients with Triple Negative Breast Cancer

  Authors:Janet Yeh, Jennifer Chun, Shira Schwartz, Annie Wang, Elizabeth Kern, Amber A. Guth, et al.From:International Journal of Breast Cancer (Vol. 2017) Peer-Reviewed

  Annual 20173,423 words Report 1330LPurpose. The purpose of this study was to compare and contrast the clinical characteristics of the triple negative breast cancer (TNBC) and non-TNBC patients, with a particular focus on genetic susceptibility and risk...

• Evaluation of CD30/CD4/CD8 in triple-negative invasive ductal carcinoma of breast in association with clinicopathological prognostic factors

  Authors:Amir Jafarian, Aida Tasbandi, Hamed Gilan, Maryam Sheikhi, and Nema RoshanFrom:Indian Journal of Pathology and Microbiology (Vol. 61, Issue 4) Peer-Reviewed

  October-December 20182,851 words Report 1790LByline: Amir. Jafarian, Aida. Tasbandi, Hamed. Gilan, Maryam. Sheikhi, Nema. Roshan Background: Triple-negative breast cancer (TNBC) lacks the benefits of receptor-targeted therapeutic strategies. The limitations in...

• Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing [beta]-catenin

  Authors:Honghong Shen, Wenpeng Yan, Jinyang Yuan, Ziyue Wang, and Chen WangFrom:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  June 7, 20196,656 words Report 1470LBackground The chemotherapy-resistance of triple-negative breast cancer (TNBC) remains a major challenge. The Nek2B kinase and [beta]-catenin serve as crucial regulators of mitotic processes. The aim of this study...

• Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype

  Authors:Yohei Funakoshi, Ying Wang, Takashi Semba, Hiroko Masuda, David Hout, Naoto T. Ueno, et al.From:PLoS ONE (Vol. 14, Issue 9) Peer-Reviewed

  Sept. 18, 20194,430 words Report 1520LBackground Inflammatory breast cancer (IBC) is an aggressive form of breast cancer. The triple-negative subtype of IBC (TN-IBC) is particularly aggressive. Identification of molecular differences between TN-IBC and...

• Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients.

  Authors:Debadrita Ray, Senjuti Gupta, Arka De, Parul Jain, Nirmal Bhattacharya, and Pranab BiswasFrom:Journal of Cancer Research and Therapeutics (Vol. 18, Issue 6) Peer-Reviewed

  Oct-Dec 20224,090 words Report 1710LByline: Debadrita. Ray, Senjuti. Gupta, Arka. De, Parul. Jain, Nirmal. Bhattacharya, Pranab. Biswas Background: Triple negative breast carcinoma (TNBC) has the highest mortality among all the breast carcinoma subtypes,...

• Androgen receptor expression in triple negative breast cancer - Study from a tertiary health care center in South India

  Authors:Rashmi Patnayak, Amitabh Jena, Dandumudu Bhargavi, and Amit ChowhanFrom:Indian Journal of Medical and Paediatric Oncology (Vol. 39, Issue 1) Peer-Reviewed

  January-March 20182,230 words Report 1560LByline: Rashmi. Patnayak, Amitabh. Jena, Dandumudu. Bhargavi, Amit. Chowhan Background: The treatment of breast cancer is based on a multi-modality approach. Analysis of the hormone receptor has been accepted as a...

• New Therapeutic Strategies for Triple-Negative Breast Cancer

  Authors:Borbala Szekely, Andrea L.M. Silber, and Lajos PusztaiFrom:Oncology (Vol. 31, Issue 2) Peer-Reviewed

  Feb. 20175,578 words Report 1810LRelatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is...

• MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

  Authors:Paul Jank, Claire Gehlhaar, Lederer Bianca, Fontanella Caterina, Schneeweiss Andreas, Thomas Karn, et al.From:PLoS ONE (Vol. 15, Issue 8) Peer-Reviewed

  Aug. 25, 20204,388 words Report 1460LAuthor(s): Paul Jank 1, Claire Gehlhaar 2,3, Lederer Bianca 4, Fontanella Caterina 5, Schneeweiss Andreas 6, Thomas Karn 7, Frederik Marmé 8, Hans-Peter Sinn 9, Marion van Mackelenbergh 10, Bruno Sinn 11, Dirk-Michael...

• Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study.

  Authors:Haosheng Tan and Deyuan FuFrom:Journal of Cancer Research and Therapeutics (Vol. 19, Issue 8) Peer-Reviewed

  Apr. 20232,377 words Report 1370LByline: Haosheng. Tan, Deyuan. Fu Introduction: Age at diagnosis has shown significant effect on the prognosis in breast cancer patients. However, whether age is an independent risk factor remains controversial....

• Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

  Authors:Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings, Karolina Sikorska, Koen K. van de Vijver, Michiel de Maaker, et al.From:Nature Medicine (Vol. 25, Issue 6) Peer-Reviewed

  June 201912,497 words Report 1510LThe efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer (TNBC) is low.sup.1-5, highlighting a need for strategies that render the...

• Tumor analysis: freeze-thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells

  Authors:Matthieu Le Gallo, Thibault de la Motte Rouge, Amanda Poissonnier, Vincent Lavoun, Patrick Tas, Jean Leveque, et al.From:BMC Research Notes (Vol. 11, Issue 1) Peer-Reviewed

  June 20, 20183,307 words Report 1390LObjective The use of novel methods to characterize living tumor cells relies on well-conceived biobanks. Herein, we raised the question of whether the composition of fresh and freeze/thawed dissociated tumor samples...

• Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer

  Authors:Maria Karmella Apaya, Jeng-Yuan Shiau, Guo-Shiou Liao, Yu-Jen Liang, Chia-Wei Chen, Hsin-Chou Yang, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  May 9, 201911,890 words Report 1620LBackground Current prognostic tools and targeted therapeutic approaches have limited value for metastatic triple negative breast cancer (TNBC). Building upon current knowledge, we hypothesized that...

• SCYL1 does not regulate REST expression and turnover

  Authors:Sebastien Gingras, Emin Kuliyev, and Stephane PelletierFrom:PLoS ONE (Vol. 12, Issue 6) Peer-Reviewed

  June 1, 20173,873 words Report 1390LA recent study identified SCYL1 as one of the components of the oncogenic STP axis, which promotes triple-negative breast cancer by regulating degradation of the REST tumor suppressor. Contrary to the findings of that...

• Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

  Authors:Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T. Conlon, et al.From:PLoS ONE (Vol. 18, Issue 3) Peer-Reviewed

  Mar. 15, 20237,854 words Report 1470LTriple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR)...

• Management of triple-negative invasive ductal cell carcinoma

  Authors:Zil-E-Ali Ahsan, Assad Salman, and Thomas ToddFrom:Translational Surgery (Vol. 1, Issue 4) Peer-Reviewed

  October-December 20162,324 words Case study 1600LByline: Zil-e-Ali. Ahsan, Assad. Salman, Thomas. Todd We reported a case of triple-negative breast cancer who presented to our medical center with a mass in the upper outer quadrant of the left breast. The age of the...

• Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

  Authors:Sara Morcillo-Garcia, Maria del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, Javier Perez-Peña, Miriam Nuncia-Cantarero, Balázs Gyorffy, et al.From:PLoS ONE (Vol. 14, Issue 4) Peer-Reviewed

  Apr. 16, 20194,192 words Report 1390LPurpose Epigenetic regulating proteins like histone methyltransferases produce variations in several functions, some of them associated with the generation of oncogenic processes. Mutations of genes involved in these...

• The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.

  Authors:Olga Caramelo, Cristina Silva, Francisco Caramelo, Cristina Frutuoso, and Teresa Almeida-SantosFrom:Hereditary Cancer in Clinical Practice (Vol. 17, Issue 1) Peer-Reviewed

  Mar. 25, 20194,933 words Report 1410LBackground Triple negative breast cancers (TNBC) are associated with an aggressive clinical course, earlier recurrence and short survival. BRCA - mutated tumours represent up to 25% of all TNBC. BRCA status is being...

• Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer

  Authors:Zhaoyun Liu, Kewen He, Qinghua Ma, Qian Yu, Chenyu Liu, Isabella Ndege, et al.From:PLoS ONE (Vol. 12, Issue 5) Peer-Reviewed

  May 22, 20176,041 words Report 1440LEpidermal growth factor receptor (EGFR) is over-expressed in about 50% of Triple negative breast cancers (TNBCs), but EGFR inhibitors have not been effective in treating TNBC patients. Increasing evidence supports that...

• An institutional analysis of clinicopathological features of triple negative breast cancer

  Authors:D. Sharma and G. SinghFrom:Indian Journal of Cancer (Vol. 53, Issue 4) Peer-Reviewed

  October-December 20161,724 words Report 1550LByline: D. Sharma, G. Singh AIM: Most common breast cancer in India among female is breast cancer. This is heterogeneous disease, one of the subtypes, triple negative breast cancer (TNBC) defined as no expression of...

• miR205 inhibits stem cell renewal in SUM159PT breast cancer cells

  Authors:Victor Mayoral-Varo, Annarica Calcabrini, Maria Pilar Sanchez-Bailon, and Jorge Martin-PerezFrom:PLoS ONE (Vol. 12, Issue 11) Peer-Reviewed

  Nov. 28, 20175,420 words Report 1440LmiR205 has a dual activity, as tumor suppressor and as oncogene. Here we analyzed the impact of miR205 ectopic expression in the initial tumorigenic processes of SUM159PT, a triple negative breast cancer cell line with...